



Entry into an Equity Joint Venture Contract on the Establishment of the Sino-Singapore Oncology Hospital

The Board of Directors (the “**Board**” or “**Directors**”) of TalkMed Group Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) refers to the Company’s announcement dated 29 August 2018 on the Entry into Collaboration Framework Agreement with the People’s Government of Yongchuan District, Chongqing Municipality, and is pleased to update shareholders that the Company’s subsidiary, TalkMed Chongqing Pte. Ltd. (“**TMCQ**”) has, on 11 September 2019, entered into an equity joint venture contract (the “**JV Contract**”) with Chongqing Yongchuan District People’s Hospital (“**YCDPH**”) for the purpose of establishing a Sino-Singapore Oncology Hospital in Yongchuan District, Chongqing, the People’s Republic of China (the “**Hospital**”).

Pursuant to the JV Contract, the Hospital will be independently operated by a joint venture company (the “**JV Company**”) to be established by TMCQ and YCDPH, subject to the approval of the local authority, Administration for Market Regulation.

The JV Company will have a registered capital of RMB 40.0 million (equivalent to approximately SGD 7.8 million). TMCQ and YCDPH will hold 60% and 40% equity interest in the JV Company respectively. It is envisaged that the Hospital will provide, *inter alia*, medical oncology (including infusion therapy), radiotherapy, diagnostic services, palliative therapy, surgeries and ancillary services. The JV Company aims to leverage on the advanced experience and technology of China and Singapore in the field of oncology treatment, and to build a high-end specialised oncology hospital that will help oncology patients recover and improve their quality of life.

The Group intends to fund its share of the registered capital of the JV Company through its internal resources. The joint venture is not expected to have any material impact on earnings per share or net tangible assets per share of the Group for the financial year ending 31 December 2019.

None of the Directors or substantial shareholders of the Company has any interest, direct or indirect, in the joint venture other than through their shareholdings in the Company.

By Order of the Board

Ang Peng Tiam
Chief Executive Officer
13 September 2019

*This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, Hong Leong Finance Limited (the “**Sponsor**”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”). This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, Telephone number: (65) 6415 9886